Related Experiment Video
Updated: Jun 10, 2025

Induction and Analysis of Epithelial to Mesenchymal Transition
Published on: August 27, 2013
PLOD1 promote proliferation and migration with glycolysis via the Wnt/β-catenin pathway in THCA
Wei Cong1, Jingfu Sun1, Zhanyu Hao1
1Department of Thyroid Surgery, The Second Hospital of Shandong University, Shandong University, Shandong Province, PR China.
Abstract:
THCA (Thyroid carcinoma) is the most common endocrine malignancy in the world. The PLOD1 is highly expressed in THCA, but the mechanism is still unclear. It is found that the cell proliferation and migration were inhibited in si-PLOD1 group, and promoted with PLOD1 overexpression. MAZ is the transcription factor of PLOD1. The cell activities induced MAZ were reversed by si-PLOD1. The Glucose uptake, lactate production and ATP/ADP ratio were decreased with si-PLOD1. The glycolysis related proteins GLUT1, HK2, PFKP, PKM2, LDHA and Wnt/β-catenin pathway proteins WNT5A, cyclin D1, β-catenin were inhibited, GSK-3β is increased in si-PLOD1 group. BML-284 could reversed the si-PLOD1 effects on cell activities and Wnt/β-catenin pathway. The tumor xenografts were inhibited in si-PLOD1 group. As a potential therapeutic target, PLOD1 is regulated by MAZ in THCA. PLOD1 depletion could inhibit THCA cell proliferation and metastasis by glycolysis, which is inhibited by Wnt/β-catenin pathway in THCA.
Insights
Thyroid carcinoma (THCA) cell growth and metastasis are inhibited by targeting PLOD1. This mechanism involves the regulation of glycolysis and the Wnt/β-catenin pathway, suggesting PLOD1 as a potential therapeutic target.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Thyroid carcinoma (THCA) is a prevalent endocrine malignancy.
- Lysyl hydroxylase 1 (PLOD1) is overexpressed in THCA, but its functional role remains unclear.
- MAZ acts as a transcription factor for PLOD1.
Purpose of the Study:
- To investigate the role of PLOD1 in THCA progression.
- To elucidate the regulatory mechanisms of PLOD1 in THCA.
- To explore PLOD1 as a potential therapeutic target for THCA.
Main Methods:
- Utilized si-PLOD1 to deplete PLOD1 expression and PLOD1 overexpression in THCA cells.
- Assessed cell proliferation, migration, glucose uptake, lactate production, and ATP/ADP ratio.
- Analyzed key glycolysis and Wnt/β-catenin pathway proteins.
- Investigated the effect of BML-284, a Wnt/β-catenin inhibitor.
- Evaluated tumor xenograft growth in vivo.
Main Results:
- PLOD1 depletion inhibited THCA cell proliferation and migration, while PLOD1 overexpression promoted these activities.
- Glucose metabolism, including uptake, lactate production, and ATP/ADP ratio, was reduced upon PLOD1 depletion.
- Expression of glycolysis proteins (GLUT1, HK2, PFKP, PKM2, LDHA) and Wnt/β-catenin pathway proteins (WNT5A, cyclin D1, β-catenin) was downregulated, with increased GSK-3β.
- BML-284 reversed the effects of si-PLOD1 on cell activities and the Wnt/β-catenin pathway.
- Tumor xenograft growth was significantly inhibited in the si-PLOD1 group.
Conclusions:
- PLOD1, regulated by MAZ, plays a crucial role in THCA progression.
- PLOD1 depletion inhibits THCA cell proliferation and metastasis by suppressing glycolysis via the Wnt/β-catenin pathway.
- PLOD1 represents a promising therapeutic target for thyroid carcinoma.
Related Concept Videos
Canonical Wnt Signaling Pathway
Abnormal Proliferation
Non-Canonical Wnt Signaling Pathways
Mitogens and the Cell Cycle
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

